新药研发国际化合作.pptVIP

Confidential 药物研发发展历史 新药研发是一个漫长充满风险的过程 价值链: 研发费用的去向 制药行业传统模式仍然有效? 新药开发与投入的不对称 制药行业商业模式的转变 行业高度依赖许可策略/合作 合作收入对生物技术公司愈加重要 生物技术公司与大药厂的新兴合作项目递增 对外许可交易价值陡增 交易额概况 药物研发价值链分析 中国的研发优势 Large and high quality talent pool Over 5 million college graduate annually Overseas returnees combined with local talent Abundant preclinical animal resources and huge naive patient population Attract more capital in life science sector China life science VC/PE funds total over $1 B Large US/Europe funds move into China Supportive government policies Gene therapy and stem cell research Building infrastructure to support RD Fast growing domestic market 尤其是药物研发服务行业 跨国公司进入中国的商业模式 “Brick and Mortar”- Build your own RD facility in China Mostly European Pharmaceutical companies, e.g. Novartis, Roche, GSK “Virtual business model”- Work with CROs and strategic partners Risk sharing approaches- pharmaceutical RD network: Lilly/HMPL Partnership Fee based CRO services Active licensing in programs “Hybrid Model”- Set up JV and China fund/direct investments 中国自主新药研发仍处于早期阶段 和记黄埔医药简介 公司目标：立足中国，面向世界，开发出具有自主知识产权的、世界一流水准的新药。 公司背景：2002年由和记黄埔资助成立，致力于中药国际化及新药的研发。 为了同一个梦想我们走到了一起… …组成了经验丰富的和黄管理团队… 毕业于北美一流的大学，并在美国的制药和生物技术公司有10到20年的成功工作经验，近一半成员来自辉瑞制药的美国研发中心 参与了多个上市产品和临床项目的研发工作。上市产品2007年的销售额超过80亿美元 在国际期刊发表论文200多篇，国际授权专利100多篇 利用中国优势加速药物研发进程 高度重视战略合作和联盟 和黄-礼来合作：中国制药行业的里程碑交易 合作模式分析 Collaborate on the discovery and development of pharmaceutical compounds focused on targets in oncology and inflammation Lilly provides the starting compounds, HMPL responsible for activities to move the compounds to candidate phase Upfront payment, annual research funding, milestones and royalties on global sales. Total milestones $20-29 million per candidate Win-win partnerships for both companies Expanded in November 2008 Limited capital and fixed asset investments Access to low cost resources Leverage partners capital Cost: Access to non dilutive capital Global market upside without large investment and risk Balanced portfo